Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lundbeck And Otsuka In Alzheimer’s Pact

by Rick Mullin
April 1, 2013 | A version of this story appeared in Volume 91, Issue 13

Denmark’s Lundbeck and Otsuka Pharmaceutical, a Japanese drugmaker, have entered a licensing agreement involving Lundbeck’s Lu AE58054, a selective 5HT6 receptor antagonist, which is being developed as a treatment for Alzheimer’s disease. Under the deal, Lundbeck grants Otsuka codevelopment and co-commercialization rights for Lu AE58054 in North America, Europe, and East Asia, including Japan. Otsuka will pay $150 million up front and as much as $675 million in milestone payments. The companies plan to launch Phase II clinical trials later this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.